Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of RAY1216 and the Effect of Food on RAY1216 Pharmacokinetics in Healthy Adult Participants

Next Previous
Trial Profile

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of RAY1216 and the Effect of Food on RAY1216 Pharmacokinetics in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leritrelvir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Guangdong Raynovent Biotech

Most Recent Events

  • 28 Apr 2023 New trial record
  • 23 Mar 2023 According to National Medical Products Administration Media Release, Leritrelvir Tablets of Guangdong Raynovent Biotech Co., Ltd has been approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top